|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_on1027476923 |
| 003 |
OCoLC |
| 005 |
20231120010247.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
180306s2018 enk ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d OPELS
|d N$T
|d YDX
|d EBLCP
|d NLE
|d UAB
|d OCLCF
|d UPM
|d D6H
|d CASUM
|d OCLCO
|d OCLCQ
|d INT
|d OCLCQ
|d AU@
|d U3W
|d OCLCO
|d OCLCA
|d LVT
|d OCLCA
|d OCLCQ
|d UKAHL
|d UKMGB
|d OCLCQ
|d S2H
|d OCLCO
|d UX1
|d VT2
|d OCLCQ
|d OCLCO
|d K6U
|d OCLCQ
|d OCLCO
|
| 015 |
|
|
|a GBB818454
|2 bnb
|
| 016 |
7 |
|
|a 018693933
|2 Uk
|
| 019 |
|
|
|a 1027815619
|a 1028036622
|a 1028081612
|a 1030531676
|a 1229580145
|a 1235833051
|
| 020 |
|
|
|a 9780128119624
|q (electronic bk.)
|
| 020 |
|
|
|a 0128119624
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128119457
|q (print)
|
| 020 |
|
|
|z 0128119454
|
| 035 |
|
|
|a (OCoLC)1027476923
|z (OCoLC)1027815619
|z (OCoLC)1028036622
|z (OCoLC)1028081612
|z (OCoLC)1030531676
|z (OCoLC)1229580145
|z (OCoLC)1235833051
|
| 050 |
|
4 |
|a HD9665.4
|
| 060 |
|
4 |
|a 2018 E-712
|
| 060 |
|
4 |
|a QV 736.1
|
| 072 |
|
7 |
|a BUS
|x 070000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 338.4/76151
|2 23
|
| 245 |
0 |
0 |
|a Equitable access to high-cost pharmaceuticals /
|c edited by Zaheer-Ud-Din Babar.
|
| 264 |
|
1 |
|a London, United Kingdom :
|b Academic Press, an imprint of Elsevier,
|c 2018.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed March 7, 2018).
|
| 500 |
|
|
|a Includes index.
|
| 505 |
0 |
|
|a Cover; Title Page; Copyright Page; Dedication; Contents; Contributors; Foreword; Chapter 1 -- Access to High Cost Medicines: An Overview; Abbreviations; 1.1 -- Defining HCMs; 1.2 -- Value of HCMs; 1.3 -- Accessibility of HCMs; 1.4 -- Approaches for promoting access to HCMs; 1.5 -- Conclusion; Note; References; Chapter 2 -- Health Technology Assessment; 2.1 -- Introduction; 2.2 -- What is health technology assessment (hta)?; 2.3 -- Technologies; 2.4 -- Principles underpinning HTA processes; 2.5 -- Evidence-based decision-making for the subsidy of health technologies.
|
| 505 |
8 |
|
|a 2.5.1 -- Criteria Used to Inform Subsidy Decisions2.5.2 -- Threshold for Value for Money; 2.5.3 -- Considering Multiple Criteria in Decision-making; 2.6 -- Who�a#x80;#x99;s involved? Stakeholders at the table; 2.7 -- Future directions in health technology assessment for high cost medicines; 2.8 -- Summary; References; Chapter 3 -- High-Cost Medicines in England; 3.1 -- Introduction; 3.2 -- Background; 3.2.1 -- Policy in History; 3.2.2 -- National Arrangements; 3.2.3 -- NICE Guidance; 3.2.4 -- The Carter Review; 3.3 -- High-cost drugs; 3.3.1 -- Specialised Services; 3.3.2 -- Cancer Drugs Fund.
|
| 505 |
8 |
|
|a 3.3.3 -- Hospital Medicines Optimisation3.4 -- The way ahead; 3.5 -- Conclusions; References; Further Reading; Chapter 4 -- Managed Entry Agreements and High Cost Medicines (European Perspective); 4.1 -- Rationale for mea; 4.2 -- Definition and taxonomy of mea; 4.3 -- Diffusion of mea in europe; 4.4 -- Impact evaluation and future perspectives; References; Chapter 5 -- Setting a Public Health Agenda to Support Access to High-Cost Medicines; 5.1 -- Introduction; 5.2 -- The emerging significance of the impact of high-cost medicines; 5.3 -- European cooperation; 5.4 -- G7 and G20.
|
| 505 |
8 |
|
|a 5.5 -- The un high-level panel on access to medicines5.6 -- Who fair pricing forum; 5.6.1 -- What Is a Fair Price? And How Is Such a Fair Price to Be Achieved?; 5.6.2 -- Towards the Fair Pricing System; 5.7 -- Conclusion; Acknowledgements; References; Chapter 6 -- Human Rights and Intellectual Property for Universal Access to New Essential Medicines; 6.1 -- Introduction; 6.2 -- Access to essential medicines in the era of intellectual property and human rights; 6.2.1 -- The WTO TRIPS Agreement�a#x80;#x94;Globalising Intellectual Property Rules; 6.2.2 -- HIV and the Drive for Change in Intellectual Property.
|
| 505 |
8 |
|
|a 6.2.3 -- The Emergence of Access to Essential Medicines in the Right to Health6.2.4 -- Doha Declaration on TRIPS and Public Health; 6.2.5 -- Patents and New Essential Medicines; 6.3 -- Human rights obligations of governments; 6.3.1 -- Maximum Available Resources; 6.3.2 -- Efficient Use of Government Resources; 6.3.3 -- Prioritising Medicines for Reimbursement; 6.3.4 -- Use of Price Control Mechanisms and TRIPs Flexibilities; 6.4 -- Protecting access to medicines in international fora; 6.4.1 -- Human Rights Obligations of the Pharmaceutical Industry; 6.5 -- Conclusion; References; Further reading.
|
| 505 |
8 |
|
|a Chapter 7 -- Access to High Price Medicines in Portugal.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 650 |
|
0 |
|a Drugs
|x Prices.
|
| 650 |
|
0 |
|a Drugs
|x Prices
|x Law and legislation.
|
| 650 |
1 |
2 |
|a Pharmacy
|x methods
|0 (DNLM)D010604Q000379
|
| 650 |
2 |
2 |
|a Economics, Pharmaceutical
|0 (DNLM)D017850
|
| 650 |
2 |
2 |
|a Pharmacy
|x organization & administration
|0 (DNLM)D010604Q000458
|
| 650 |
|
6 |
|a M�edicaments
|x Prix.
|0 (CaQQLa)201-0059421
|
| 650 |
|
6 |
|a Pharmaco�economie.
|0 (CaQQLa)201-0304191
|
| 650 |
|
7 |
|a BUSINESS & ECONOMICS
|x Industries
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a Drugs
|x Prices
|2 fast
|0 (OCoLC)fst00898879
|
| 650 |
|
7 |
|a Drugs
|x Prices
|x Law and legislation
|2 fast
|0 (OCoLC)fst00898883
|
| 655 |
|
4 |
|a Internet Resources.
|
| 700 |
1 |
|
|a Babar, Zaheer-ud-din,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Equitable access to high-cost pharmaceuticals.
|d London, United Kingdom : Academic Press, an imprint of Elsevier, 2018
|z 0128119454
|z 9780128119457
|w (OCoLC)1004366650
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128119457
|z Texto completo
|
